OncoMatch/Clinical Trials/NCT06216301
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Is NCT06216301 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including NovoTTF-200T and Pembrolizumab for metastatic non-small cell lung cancer.
Treatment: NovoTTF-200T · Pembrolizumab · Platinum based chemotherapy — This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
EGFR sensitizing mutation ... is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.
Required: ALK fusion
ALK translocation ... is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.
Required: ROS1 rearrangement
ROS1 ... is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.
Required: RET rearrangement
RET targetable gene rearrangement ... is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.
Required: MET exon 14 skipping mutation
METex14 skipping mutation ... is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.
Required: NTRK1 fusion
NTRK1 ... gene fusion ... is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.
Required: NTRK2 fusion
NTRK2 ... gene fusion ... is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.
Required: BRAF V600 mutation
BRAF V600 mutations ... is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Exception: adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease completed at least 12 months prior to the development of metastatic disease
Have not received prior systemic treatment for their metastatic NSCLC. Subjects who received adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease are eligible if the therapy was completed at least 12 months prior to the development of metastatic disease.
Cannot have received: anti-PD-1, PD-L1, or PD-L2 agent or antibody or small molecule targeting other immuno-regulatory receptors or mechanisms
Had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors or mechanisms in the 12 months prior to randomization.
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate end-organ function
Liver function
Adequate end-organ function
Adequate hematologic and end-organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Central Alabama Research · Birmingham, Alabama
- Western Regional Medical Center, LLC · Goodyear, Arizona
- St. Jude Herritage Medical Group · Fullerton, California
- Hoag Family Cancer Institute - Hoag Memorial Hospital · Newport Beach, California
- Sutter Institute for Medical Research · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify